Article excerpt
Chemical compounds with high therapeutic value often come with an impossible catch: they exist in tiny amounts in rare plants, fungi, or other natural sources. Extracting them can take tons of raw material, leaving environmental scars, or require toxic petrochemical processes that produce hazardous waste. For decades, scientists tried to overcome these limits by using synthetic biology: engineering living cells to produce molecules, but scaling these methods from lab to factory remained a near-impossible challenge. Yields were low, cells resisted foreign tasks, and production often failed to reach commercial levels. A new class of technology is emerging to tackle this challenge: exozymes.
Michael Heltzen, CEO of eXoZymes, describes the breakthrough simply: "Cells weren't built to manufacture what we need, and they fight us every step of the way as they only want to make chemicals they themselves benefit from and only at the amount they need it. Using AI-enhanced eXoZymes, we flip the model, as there are no living cells in our biosolutions."
eXoZymes Safe Harbor
This post includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this post regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.